Low incidence of nephrotoxicity following intravenous administration of iodinated contrast media: a prospective study
- 18 Downloads
To estimate the incidence of contrast-induced acute kidney injury (CI-AKI) after intravenous (iv) iodinated contrast material (ICM) exposure.
This prospective cohort study included all consecutive patients who underwent radiological investigations using low-osmolar iopamidol 370 mg/ml in a regional hospital over a period of 36 months, without any exclusion criteria. The estimated glomerular filtration rate (eGFR) was evaluated using the MRDR equation before (2–10 days) and after (24–36 h) radiological investigations. CI-AKI was defined as a ≥ 25% decrease in eGFR from baseline. CI-AKI incidence was estimated using a binomial distribution. The association between CI-AKI and demographic and clinical characteristics was modeled using logistic regression.
The study included 1541 patients with a median age of 68 (1st–3rd quartiles 58–76) years with various comorbidities, 30% of whom had pre-existing CKD. Patients affected by stage III or IV chronic kidney disease (CKD) received an infusion of 0.9% normal saline (1.0–1.5 ml/kg/h) before and after iso-osmolar iodixanol administration. CI-AKI was observed in 33 patients (2.1%, 95% CI 1.5–3.0). The logistic regression analysis showed that antibiotic and statin therapies were significantly associated with CI-AKI. The probability of developing CI-AKI decreased by 80% in patients taking statins (OR = 0.20, 95% CI 0.03; 0.68) and increased approximately three times in patients with antibiotic therapy compared with those who did not take statins and antibiotics (OR = 2.92, 95% CI 1.21; 6.36).
Our data suggest that low-osmolar iopamidol carries a low incidence of nephrotoxicity, even in subjects with various comorbid conditions or reduced renal function.
• IV administration of ICM carries a low incidence of nephrotoxicity, which was transient in observed patients.
• Statin therapy is negatively associated with AKI in patients exposed to ICM.
• Pre-existing impairment of renal function is not associated with AKI in patients exposed to ICM.
KeywordsContrast material Incidence Glomerular filtration rate Renal insufficiency
Contrast-induced acute kidney injury
Chronic kidney disease
Estimated glomerular filtration rate
Intravenous iodinated contrast media
This study has received funding by Agenzia Italiana del Farmaco (AIFA) (FARM823BHC).
Compliance with ethical standards
The scientific guarantor of this publication is Salvatore Amoroso.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
Luigi Ferrante and Edlira Skrami have significant statistical expertise.
Written informed consent was obtained from all subjects (patients) in this study.
Institutional Review Board approval was obtained.
• Performed at one institution
- 2.Mehran R, Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl:S11–S15Google Scholar
- 7.Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA (2009) Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR Am J Roentgenol 192:711–718Google Scholar
- 13.Contrast media safety committee (2013) ESUR guidelines on contrast media, version 81 http://www.esur.org/guidelines/
- 14.National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39:S1Google Scholar
- 15.Group KDIGoAKIW (2012) KDIGO clinical practice guideline for acute kidnay injury. Kidney Int Suppl 2:138. https://doi.org/10.1038/kisup.2012.1
- 16.R Core Team (2016) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. Retrieved from https://www.r-project.org
- 18.Andreucci M, Faga T, Pisani A, Sabbatini M, Russo D, Michael A (2014) Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal 2014:823169Google Scholar
- 21.van der Molen AJ, Reimer P, Dekkers IA et al (2018) Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28:2856–2869CrossRefGoogle Scholar
- 24.van der Molen AJ, Reimer P, Dekkers IA et al (2018) Post-contrast acute kidney injury - part 1: definition, clinical features, incidence, role of contrast medium and risk factors : recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28:2845–2855CrossRefGoogle Scholar
- 26.Nijssen EC, Nelemans PJ, Rennenberg RJ, van Ommen V, Wildberger JE (2018) Prophylactic intravenous hydration to protect renal function from intravascular iodinated contrast material (AMACING): long-term results of a prospective, randomised, controlled trial. EClinicalMedicine 4-5:109–116Google Scholar
- 27.Liu Y, Li H, Chen S et al (2016) Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency. J Am Heart Assoc 5:e003171Google Scholar
- 38.Solomon R (2014) Contrast media: are there differences in nephrotoxicity among contrast media? Biomed Res Int 2014:934947Google Scholar
- 40.Heinrich MC, Häberle L, Müller V, Bautz W, Uder M (2009) Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250:68–86Google Scholar
- 42.Leoncini M, Toso A, Maioli M et al (2013) Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol 63:71–79Google Scholar
- 44.Park SH, Jeong MH, Park IH et al (2016) Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 212:100–106CrossRefGoogle Scholar